The Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy

  title={The Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy},
  author={Robert D. Loberg and Deborah A. Bradley and Scott A. Tomlins and Arul M. Chinnaiyan and Kenneth J. Pienta},
  journal={CA: A Cancer Journal for Clinicians},
The last decade has seen an explosion in knowledge of the molecular basis and treatment of cancer. The molecular events that define the lethal phenotype of various cancers—the genetic and cellular alterations that lead to a cancer with a poor or incurable prognosis—are being defined. While these studies describe the cellular events of the lethal phenotype of cancer in detail, how these events result in the common clinical syndromes that kill the majority of cancer patients is not well… 
Tracing the origins of metastasis
  • D. Nguyen
  • Biology, Medicine
    The Journal of pathology
  • 2011
There is a renewed conceptual and technological focus on characterizing the cellular and genetic heterogeneity within tumours, to ultimately trace the origins of metastatic cells in different cancers.
Molecular Pathology of Cancer Metastasis: Suggestions for Future Therapy
This chapter describes how a cancer cell acquires metastatic capability and then how it can engage the metastases in battle by using the most rationale and useful approaches.
Metastasis: an early event in cancer progression
Early intervention on metastasis should be applied among cancer patients in clinical settings and biological mechanism of metastasis at an early stage in both intracellular and extracellular context is reviewed.
Ecology meets cancer biology: The cancer swamp promotes the lethal cancer phenotype
As they grow, tumors fundamentally alter their microenvironment, disrupting the homeostasis of the host organ and eventually the patient as a whole, and this “cancer swamp” has genetic and epigenetic effects at the local ecosystem level to promote metastasis and at the systemic host level to induce cytokine-mediated lethal syndromes.
A multi-targeted approach to treating bone metastases
Successful clinical outcomes will be the result of co-targeting and interrupting the various tumor-supportive elements and cooperating pathways at the level of the tumor cell, the primary and metastatic microenvironments, and systemic cancer effects, leading to a “scaled network disruption” to undermine the disease state.
Ski: Double roles in cancers.
Physiologic and molecular characterization of a novel murine model of metastatic head and neck cancer cachexia
A metastatic model of human papilloma virus (HPV) positive head and neck squamous cell carcinoma is characterized that recapitulates the cardinal clinical and molecular features of cancer cachexia.
Collapse of Intra-Tumor Cooperation Induced by Engineered Defector Cells
It is shown that genetically modified cancer cells in which the gene for an essential growth factor is knocked out can spread in a population of cells that produce that growth factor, leading to an overall reduction in proliferation—a proof of principle for a potential treatment that harnesses clonal selection by impairing intra-tumor cooperation.
Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse
The C26 tumor, ectopically implanted in mice, is an undifferentiated carcinoma, which should be referred to as such and not as adenocarcinoma, a common misconception, and represents a well standardized experimental model for research on cancer cachexia.


A molecular signature of metastasis in primary solid tumors
It is found that solid tumors carrying the gene-expression signature were most likely to be associated with metastasis and poor clinical outcome, suggesting that the metastatic potential of human tumors is encoded in the bulk of aPrimary tumor, thus challenging the notion that metastases arise from rare cells within a primary tumor that have the ability to metastasize.
Host genetics and tumour metastasis
  • K. Hunter
  • Medicine, Biology
    British Journal of Cancer
  • 2004
The observations could be reconciled by combining the theories, with genetic background influencing both metastatic efficiency and predictive gene expression profiles, upon which, subsequently, metastasis-promoting mutational and epigenetic events occur.
The clonal evolution of tumor cell populations.
Each patient's cancer may require individual specific therapy, and even this may be thwarted by emergence of a genetically variant subline resistant to the treatment, which should be directed toward understanding and controlling the evolutionary process in tumors before it reaches the late stage usually seen in clinical cancer.
The Molecular Signature of Metastases of Human Hepatocellular Carcinoma
It is found that the molecular signature of primary hepatocellular carcinoma (HCC) is very similar to that of their corresponding metastases, while it differs significantly in primary HCCs with or without metastasis.
Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype.
Current therapeutic strategies for targeting the prostate cancer-bone microenvironment and several single- and multiagent targeted approaches to the treatment of advanced prostate cancer that are under development are reviewed.
Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer.
The presence of a conserved BMI-1-driven pathway, which is similarly engaged in both normal stem cells and a highly malignant subset of human cancers diagnosed in a wide range of organs and uniformly exhibiting a marked propensity toward metastatic dissemination as well as a high probability of unfavorable therapy outcome, is suggested.
Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer.
The results suggest that the capacity to metastasize is an inherent feature of most breast cancers and imply that poor prognosis breast carcinomas classified either by the intrinsic gene set or the 70 prognosis genes represent distinct disease entities that seem sustained throughout the metastatic process.
Integrative molecular concept modeling of prostate cancer progression
Using laser-capture microdissection to isolate 101 cell populations, an integrative model of prostate cancer progression from benign epithelium to metastatic disease is generated and shows that analyzing gene expression signatures in the context of a compendium of molecular concepts is useful in understanding cancer biology.
Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases
Metastatic hormone-refractory prostate cancer has a heterogeneous morphology, immunophenotype, and genotype, demonstrating that “metastatic disease” is a group of diseases even within the same patient.
The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited
It is now known that the potential of a tumour cell to metastasize depends on its interactions with the homeostatic factors that promote tumour-cell growth, survival, angiogenesis, invasion and metastasis.